The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
Open accessAbstract
Background: Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is likely to cross the placental barrier; however, information on the effects of tofacitinib on pregnancy outcomes is limited. We report pregnancy and newborn outcomes among patients in UC clinical studies with prenatal (maternal/paternal) exposure to tofacitinib. Methods: Pregnancies with maternal/paternal exposure to tofacitinib were identified and outcomes reported in 5 tofacitinib UC interventional studies (up to March 2017). Outcomes from tofacitinib rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis interventional studies, and RA noninterventional postapproval safety studies, spontaneous adverse event reporting, and registry data are also reported. Results: Of 1157 patients enrolled in the UC interventional studies, 301 were women of childbearing age. Eleven cases of maternal exposure and 14 cases of paternal exposure to tofacitinib (doses of 5 mg or 10 mg twice daily) before/at the time of conception or during pregnancy were identified. Outcomes included 15 healthy newborns, no fetal deaths, no neonatal deaths, no congenital malformations, 2 spontaneous abortions, and 2 medical terminations. Outcomes across other tofacitinib studies and postmarketing cases were consistent, with a healthy newborn being the most common outcome and no fetal deaths. Conclusions: Based on the limited data available, pregnancy and newborn outcomes among patients with prenatal (maternal/paternal) exposure to tofacitinib in UC studies appear similar to those reported for other tofacitinib clinical study populations and the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maternal age and fetal loss: population based register linkage study
Andersen, A.-M. N. (2000) · BMJ · doi:10.1136/bmj.320.7251.1708 · Cited by 1,690
In utero analysis of fetal growth: a sonographic weight standard
Hadlock, F. P., Harrist, R. B., & Martinez-Poyer, J. (1991) · Radiology · doi:10.1148/radiology.181.1.1887021 · Cited by 1,281
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Torres, J., Chaparro, M., Julsgaard, M., Katsanos, K., Zelinkova, Z., Agrawal, M., Ardizzone, S., Campmans-Kuijpers, M., Dragoni, G., Ferrante, M., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac115 · Cited by 281
Pérez-Jeldres, T., Tyler, C. J., Boyer, J. D., Karuppuchamy, T., Yarur, A., Giles, D. A., Yeasmin, S., Lundborg, L., Sandborn, W. J., Patel, D. R., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00212 · Cited by 126
Metadata
- Authors
- Mahadevan, U., Dubinsky, M. C., Su, C., Lawendy, N., Jones, T. V., Marren, A., Zhang, H., Graham, D., Clowse, M. E. B., Feldman, S. R., & Baumgart, D. C.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-02
- Volume
- 24
- Issue
- 12
- Pages
- 2494-2500
- ISSN
- 1078-0998 (ISSN-L)
- 1536-4844
- OpenAlex
- W2809935712
- Cited by
- 175
- References
- 2
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.